Beijing Lingxin Borui Biotechnology

Beijing Lingxin Borui Biotechnology, also known as Link-X, is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of innovative cell therapies. The company focuses on next-generation CAR-T cell products, particularly dual-targeting and armored CAR-T technologies designed to overcome resistance and improve efficacy in hematologic malignancies and solid tumors. Its lead candidate, LX-101, is a CD19/CD22 bispecific CAR-T therapy currently undergoing clinical evaluation for B-cell malignancies. Lingxin Borui aims to provide more durable and safer treatment options for patients with refractory or relapsed cancers through its proprietary cell engineering platforms. The company has established a GMP-compliant manufacturing facility to support its clinical pipeline and future commercialization efforts.